Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The ADAPT trial: a randomized, double-blind, placebo-controlled, dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of CELZ-201

Next Previous
Trial Profile

The ADAPT trial: a randomized, double-blind, placebo-controlled, dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of CELZ-201

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 31 Dec 2025 New trial record
  • 17 Dec 2025 According to Creative Medical Technology Holdings, CELZ has reached a critical execution milestone with enrollment completion. Enrollment completion follows a previously announced positive independent Data Safety Monitoring Board (DSMB) safety review. The study incorporates rigorous safety oversight, including DSMB reviews and adverse event tracking aligned with CTCAE v5.0 standards.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top